| Literature DB >> 32914167 |
Abdul Arif Khan1, Zakir Khan2.
Abstract
Last two decades have witnessed several global infectious outbreaks. Among these, coronavirus is identified as a prime culprit ranging from its involvement in severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) to COVID-19. These infections involved in huge healthcare and economic cost incurred globally. Every time, coronavirus improved its infection ability and surprised the medical practitioners and researchers. Currently, COVID-19 is also causing numerous infections and stalled global activities. Global efforts are underway to identify potential viral targets for management of these outbreaks, but significant progress in prevention of these outbreaks is not yet achieved. We explored host-pathogen protein-protein interactions of MERS, SARS and COVID-19, and identified host targets common among all recent coronavirus outbreaks. Further, we tried to understand their potential for management of coronavirus. The common proteins involved in coronavirus host-pathogen interactions indicate their indispensable role in the pathogenesis and therefore targeting these proteins can give strategies to prevent current and future coronavirus outbreaks. Viral variability necessitates development of new therapeutic modalities for every outbreak, in contrast targeting necessary human proteins required by all coronaviruses can provide us a clue to prevent current and future coronavirus outbreaks. We found that targeting FURIN and TMPRSS2 can provide good results due to their common involvement in current and previous outbreaks. We also listed some known molecules against these two targets for their potential drug repurposing evaluation. Although, several recent studies undergoing with targeting these proteins for management of coronavirus, but safety evaluation and risk assessment must be given prime importance while targeting human proteins.Entities:
Keywords: FURIN; TMPRSS2; coronavirus; host–pathogen interactions; infection prevention
Mesh:
Substances:
Year: 2021 PMID: 32914167 PMCID: PMC7546044 DOI: 10.1093/bib/bbaa207
Source DB: PubMed Journal: Brief Bioinform ISSN: 1467-5463 Impact factor: 11.622
Figure 1Work scheme representing identification of important human targets from comparative coronavirus HPI map.
Details about coronavirus-related interactions in BioGrid
| Interacting partners | Number of interactions |
|---|---|
| Total interactions | 743 |
| Human–Human | 41 |
|
| 01 |
|
| 01 |
| MERS–MERS | 03 |
| SARS–SARS | 165 |
| SARS CoV2–SARS CoV2 | 14 |
| MERS–human/human–MERS | 02/04 |
| SARS–human/human–SARS | 142/17 |
| SARS CoV2–human/human–SARS CoV2 | 340/13 |
|
|
|
For details please refer Table S1.
Figure 2Comparative host–pathogen protein–protein interactions of MERS, SARS and SARS2. Viral proteins are indicated with different node colors (MERS: fluorescent green, SARS: yellow, SARS2: blue). Human proteins are generally indicated with red colors but common human proteins are shown with large size nodes. In addition, the proteins common among all coronaviruses are shown with sky blue color, whereas human proteins common among other pathogens are also shown with different colors. Multiple edges indicate about detection of same interaction through multiple experimental evidences.
Common human proteins found to interact with coronavirus of recent public health concern as per BioGrid database
| Sr. No. | Virus | Common human interacting proteins |
|---|---|---|
| 1 | SARS, MERS and COVID | MASP2 |
| FURIN | ||
| TMPRSS2 | ||
| 2 | SARS and COVID | ACE2 |
| MASP2 | ||
| FURIN | ||
| TMPRSS2 | ||
| BZW2 | ||
| TBK1 | ||
| SMOC1 | ||
| MARK3 | ||
| MARK2 | ||
| 3 | MERS and COVID | MASP2 |
| FURIN | ||
| TMPRSS2 | ||
| 4 | SARS and MERS | MASP2 |
| TRIM25 | ||
| FURIN | ||
| TMPRSS2 | ||
| RCHY1 |
Details of common interactors and their interaction with different coronaviruses
| Common human protein interactor | Primary function according to Uniprot | Viral interactor proteins | ||
|---|---|---|---|---|
| MERS | SARS | SARS2 | ||
| MASP2 | Activation of complement by its serum protease activity via mannose-binding lectin. Cleaves and activates C2 and C4, resulting in formation of C3 convertase | N | N | N |
| FURIN | Endoprotease with the ability to cleave at the RX(K/R)R consensus motif. Required for H7N1 and H5N1 influenza virus infection by hemagglutinin cleavage [ | S | S | S |
| TMPRSS2 | Promotes SARS-CoV and SARS-CoV-2 infections via proteolytic cleavage of Angiotensin-converting enzyme 2 (ACE2) receptor promoting viral uptake, and cleavage of spike glycoproteins of coronavirus and its activation for host cell entry [ | S | S | S |
| ACE2 | Receptor for entry of SARS-CoV and SARS-CoV-2, NL63/HCoV-NL63 | – | S | S |
| BZW2 | May be involved in neuronal differentiation | – | nsp8ab | M |
| TBK1 | Serine/threonine kinase playing an important role in inflammatory responses against foreign substances | – | nsp5ab | nsp13 |
| SMOC1 | Important roles in eye and limb development. Probably regulates differentiation of osteoblast | – | ORF7a | ORF8 |
| MARK3 | It is a serine/threonine-protein kinase [ | – | ORF9b,nsp13ab | ORF9b |
| MARK2 | It is a serine/threonine protein kinase [ | – | nsp13ab | ORF9b |
| TRIM25 | Ubiquitin E3 ligase and ISG15 E3 ligase [ | N | N | – |
| RCHY1 | E3-dependent ubiquitination and proteasomal degradation of target proteins. Involved in the cell cycle progression regulation and enhance androgen receptor (AR) transcription factor activity | nsp3ab | nsp3ab | – |
Known molecule targeting of important human interactors and their possible reactions
| Database | Human protein | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| FURIN | TMPRSS2 | ||||||||
| DrugBank | DRUGBANK ID | DB04951 | DB03600 | DB13729 | |||||
| Name | Pirfenidone (NCT04282902) | Capric acid | Camostat (NCT04353284, NCT04338906, NCT04321096, NCT04455815) | ||||||
| Drug group | Approved, investigational | Experimental | Experimental inhibitor | ||||||
| IUPHAR/BPS guide to Pharmacology | Ligand | MI-1148 [ | Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide [ | Peptide 18 [ | Furin inhibitor peptide [ | I-432 [ | Compound 5 [ | Nafamostat (NCT04418128, NCT04352400) [ | Camostat (mentioned above) |
| Action | Inhibition | Inhibition | Inhibition | Inhibition | Inhibition | Inhibition | Inhibition | Inhibition | |
| PubChem | CID/SID | 16760442 | 44584947 | 57358476 | 85101385 | 85108608 | 70 siRNA with reagent vendors | ||
| Name | Furin inhibitor I | Furin inhibitor peptide | Hexa-D-arginine (furin inhibitor II) | RNAi of TMPRSS2 (R & D) | RNAi of TMPRSS2 (R & D) | ||||
| Literature search | Luteolin | Found in several food, inhibit viral replication through furin inhibition [ | Geniposide (NPC306344) | A major iridoid glycosides of gardenia fruit predicted to inhibit TMPRSS2 during docking analysis [ | |||||
| Baicalein, oroxylin A and chrysin | Isolated from stem bark of medicinally active plant | Nafamostat (mentioned above) | Known to inhibit MERS [ | ||||||
The few clinical trials (identifier) of certain molecule for COVID-19 are also mentioned in brackets.